Quoin Pharmaceuticals Announced Interim Analysis Of First Six Patients To Complete 12 Weeks Of Treatment Met Pre-Specified Alpha Adjusted Target For Primary Endpoint With Statistical Significance

QNRX shares are trading higher after the company announced interim Phase 2/3 results showing QRX003 met the primary and key secondary endpoints with statistical significance, along with itch reduction and no serious adverse events.

8-K filing — Quoin Pharmaceuticals, Ltd. (QNRX)

Filed: 2026-08-28 AccNo: 0001104659-26-102917 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Dow Gains 100 Points; Chicago PMI Falls In August

US stocks up, Dow gains 100 points, S&P 500 and NASDAQ also rise. Communication services up 1.1%, technology down 0.3%. Chicago Business Barometer dips.

Quoin Pharmaceuticals Stock Surges Friday: What's Happening?

Shares of Quoin Pharmaceuticals are rallying Friday after pre-market updates on positive trial results and a major institutional financing.